Scholarlink

<p>Childhood obesity is a&#xa0;growing global health problem. Traditional treatment approaches were primarily limited to lifestyle modification with limited effectiveness or invasive bariatric surgery with better results but higher risks.</p><p>New pharmacological therapies are now closing the effectiveness gap between these approaches. Incretins, such as the GLP‑1 analogs liraglutide and semaglutide, have been approved by the European Medicines Agency (EMA) for children aged&#xa0;12 and older weighing over 60 kg. Promising study results in children aged 6–12&#xa0;years suggest an imminent extension of approval. Furthermore, the approval of additional medications in the coming years seems likely.</p><p>With semaglutide, besides impressive weight reduction, there was also improvement in secondary endpoints such as waist circumference, HbA1c, blood lipids, and liver parameters. The most common side effects are usually mild gastrointestinal complaints during the dose titration phase. Weight regain is expected after discontinuation of therapy.</p><p>These new medications are revolutionizing obesity therapy for children and adolescents, but raise questions about cost-effectiveness, long-term use, and appropriate integration into healthcare structures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue Therapien bei Adipositas im Kindesalter

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Julian Gomahr,
  • Daniel Weghuber

摘要

Childhood obesity is a growing global health problem. Traditional treatment approaches were primarily limited to lifestyle modification with limited effectiveness or invasive bariatric surgery with better results but higher risks.

New pharmacological therapies are now closing the effectiveness gap between these approaches. Incretins, such as the GLP‑1 analogs liraglutide and semaglutide, have been approved by the European Medicines Agency (EMA) for children aged 12 and older weighing over 60 kg. Promising study results in children aged 6–12 years suggest an imminent extension of approval. Furthermore, the approval of additional medications in the coming years seems likely.

With semaglutide, besides impressive weight reduction, there was also improvement in secondary endpoints such as waist circumference, HbA1c, blood lipids, and liver parameters. The most common side effects are usually mild gastrointestinal complaints during the dose titration phase. Weight regain is expected after discontinuation of therapy.

These new medications are revolutionizing obesity therapy for children and adolescents, but raise questions about cost-effectiveness, long-term use, and appropriate integration into healthcare structures.